Marion Cardizem SR
Generates $19 mil. sales in first quarter FY 1990 sales. First quarter sales of Marion's immediate-release Cardizem totaled $162 mil., bringing combined Cardizem line sales to $181 mil., up 39% over the same period in FY 1989. Carafate sales in the quarter were down 23% to $30 mil. Overall, Marion sales grew 15% to $237 mil.; earnings were up 29% before taking into account special charges associated with the merger with Merrell Dow.
You may also be interested in...
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.